• Aucun résultat trouvé

Supplementary Table 1:

N/A
N/A
Protected

Academic year: 2022

Partager "Supplementary Table 1:"

Copied!
7
0
0

Texte intégral

(1)

Supplementary Table 1:5yr probabilities of NRM by conditioning regimen and prognostic variable

MAC (N=781) RIC (N=1443)

N Probability%

(95% CI)

p-value N Probability (95% CI)

p-value

Disease Stage at HSCT Responding/ Stable

Relapse, Refractory, Progression Untreated

Other

150 284 302 45

30.8 (24-40) 36.7 (31-43) 33.7 (29-40) 35.8 (24-54)

0.56 27

0 52

2 54

8 10

3

31.1 (26-38) 38.4 (34-43) 34.2 (30-39) 27.1 (19-38)

0.089

Patient age (y)

<40 40-50 50-60 60-70

>70

98 218 276 179 10

20.0 (13-30) 30.6 (25-38) 36.9 (31-44) 42.7 (35-52)

NR

0.005 68 21 1 63

6 50

1 27

22.1 (14-35) 27.9 (22-35) 32.5 (29-37) 42.5 (38-47) 20.2 (9-45)

<0.001

HLA Match Matched sibling Matched unrelated Mismatched unrelated Unrelated

317 60 19 385

24.6 (20-30) 30.2 (21-45) 42.1 (24-73) 43.5 (38-50)

<0.001 55

2 10

1 41 74 9

29.6 (26-34) 35.1 (27-46) 62.2 (48-80) 36.9 (33-41)

<0.001

Karnofsky performance status (%)

100 150 27.5 (21-37) 35 30.7 (27-35)

(2)

90 80

<80 Missing

315 142 44 130

31.0 (26-37) 40.2 (33-50) 47.9 (34-66)

0.014 6

50 1 27

9 10

8 19

6

39.2 (34-46) 38.3 (30-50) 39.4 (33-47)

0.008

Co-morbidity No

Yes Missing

210 105 466

30.3 (24-38)

35.9 (31-41) 0.39 45

9 32

3 66

1

28.7 (34-38)

36.7 (33-41) 0.028

Patient / Donor CMV Match -/-

-/+

+/- +/+

Missing

204 81 156 289 51

29.8 (24-38) 38.1 (28-51) 42.0 (34-51) 31.8 (27-38)

0.11 42

9 15

8 26

4 54

6 46

32.4 (28-38) 34.3 (27-43) 37.8 (32-45) 33.7 (30-38)

0.09

(3)

Supplementary Table 2: Multivariable analysis of NRM

MAC RIC

N RR (95% CI) p-value N RR (95% CI) p-value

Patient age (y)

<40 30-50 50-60 60-70

>70

98 21 8 27

6 17

9 10

1.00 1.36 (0.8-2.2) 1.61 (0.99-2.6)

1.83 (1.1-3.1) 3.17 (1.2-8.6)

0.23 0.052 0.021 0.023

66 204 611 490 26

1.00 1.40 (0.8-2.5) 1.60 (0.96-2.8)

2.56 (1.5-4.4) 1.14 (0.4-2.9)

0.24 0.05

<0.001 0.78

HLA Match Matched Sibling Matched unrelated Mismatched unrelated Unrelated

31 7 60 19 38 5

1.00 1.24 (0.7-2.1) 1.65 (0.8-3.5) 1.79 (1.3-2.4)

0.41 0.19

<.001

525 98 39 735

1.00 1.13 (0.8-1.6) 2.26 (1.5-3.4) 1.15 (0.97-1.4)

0.21

<0.001 0.047

(4)

Karnofsky performance status (%)

100 90 80

<80 Missing

15 0 44 14 2 31

5 15

0

1.00 1.17 (0.8-1.6) 1.65 (1.1-2.4) 2.18 (1.3-3.8) 1.77 (1.1-2.8)

0.61 0.032 0.005 0.013

347 497 270 102 181

1.00 0.93 (0.7-1.2) 1.30 (0.99-1.7)

1.46 (1.0-2.1) 1.43 (1.1-1.95)

0.58 0.063 0.043 0.022

(5)

Supplementary Table 3:5yr probabilities of survival by conditioning regimen and prognostic variable

MAC (N=781) RIC (N=1443)

N Probability%

(95% CI)

p-value N Probability (95% CI)

p-value

Disease Stage at HSCT Responding/ Stable

Relapse, Refractory, Progression Untreated

Other

150 284 302 45

59.2 (51-69) 47.8 (42-55) 55.2 (49-62) 52.3 (39-70)

0.067 27

0 52

2 54

8 10

3

54.3 (48-61) 44.6 (40-50) 53.9 (50-59) 59.0 (50-70)

0.008

Patient age (y)

<40 40-50 50-60 60-70

>70

98 218 276 179 10

74.2 (66-84) 55.9 (49-64) 50.0 (44-57) 43.0 (35-52)

NR

<0.001 68 21 1 63

6 50

1 27

73.1 (63-85) 60.0 (53-68) 54.3 (50-59) 39.0 (35-44) 65.5 (48-89)

<0.001

HLA Match Matched sibling Matched unrelated Mismatched unrelated Unrelated

317 60 19 385

61.6 (56-68) 57.9 (47-72) 47.4 (30-76) 44.7 (39-51)

0.006 55

2 10

1 41 74 9

55.5 (51-60) 47.3 (38-58) 30.0 (18-49) 49.3 (45-54)

0.001

Karnofsky performance status (%)

(6)

100 90 80

<80 Missing

150 315 142 44 130

64.0 (56-73) 56.6 (51-63) 43.3 (35-53) 37.0 (25-50)

<0.001 35

6 50

1 27

9 10

8 19

6

56.0 (50-62) 56.1 (52-61) 47.0 (41-54) 35.8 (27-47)

<0.001

Patient gender Male Female

494 287

49.8 (45-55) 58.5 (53-65)

0.027 91 3 53

0

49.8 (46-54) 53.0 (49-58)

0.13

Co-morbidity No

Yes Missing

210 105 466

56.1 (49-64)

49.7 (40-62) 0.50 45

9 32

3 66

1

60.8 (55-67)

48.4 (44-54) 0.001

Patient / Donor CMV Match -/-

-/+

+/- +/+

Missing

204 81 156 289 51

59.1 (52-67) 52.4 (42-66) 46.2 (38-56) 54.4 (48-61)

0.073 42

9 15

8 26

4 54

6 46

55.3 (50-61) 51.0 (43-60) 43.7 (38-51) 52.1 (48-57)

0.009

(7)

Supplementary Table 4: Multivariable analysis of Survival

MAC RIC

N RR (95% CI) p-value N RR (95% CI) p-value

Patient age (y)

<40 40-50 50-60 60-70

>70

98 21 8 27

6 17

9 10

1.00 1.45 (0.9-2.2) 1.78 (1.2-2.7) 2.11 (1.4-3.3) 3.20 (1.2-8.4)

0.09 0.006

<0.001 0.019

66 204 611 490 26

1.00 1.35 (0.8.1-2.2)

1.60 (1.0-2.6) 2.68 (1.7-4.3) 1.31 (0.6-2.9)

0.24 0.05

<0.001 0.51

HLA Match Matched Sibling Matched unrelated Mismatched unrelated Unrelated

31 7 60 19 38 5

1.00 1.12 (0.7-1.7) 1.39( 0.7-2.6) 1.43 (1.1-1.8)

0.59 0.30 0.005

525 98 39 735

1.00 1.13 (0.8-1.6) 2.26 (1.5-3.4) 1.15 (0.97-1.4)

0.46

<0.001 0.13

Karnofsky performance status (%)

100 90 80

<80 Missing

15 0 44 14 2 31

5 15

0

1.00 1.17 (0.8-1.6) 1.65 (1.2-2.4) 2.18 (1.4-3.5) 1.77 (1.2-2.6)

0.37 0.007 0.001 0.003

347 497 270 102 181

1.00 1.01 (0.8-1.3) 1.30 (1.02-1.6)

1.86 (1.4-2.5) 1.54 (1.2-2.1)

0.96 0.032

<0.001 0.002

Patient gender

Female 28 1.0

(8)

Male 7 19

4

1.30 (1.03-1.6) 0.039

Patient / Donor CMV Match -/- -/+

+/- +/+

429 158 264 546

1.00 1.28 (0.97-1.7)

1.38 (1.1-1.7) 1.10 (0.95-1.4)

0.079 0.005 0.14

Références

Documents relatifs

Great Reed Warbler Acrocephalus arundinaceus Basra Reed Warbler Acrocephalus griseldis Upcher’s Warbler Hippolais languida Olive-tree Warbler Hippolais olivetorum Melodious

[r]

Risk of bias assessment for included RCTs.. Study

Structured summary 2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions;

a Effect of 10mM metformin on viable cell number under 21% and 1% oxygen; b Effect of increasing concentrations of metformin on viable cell number of astrocytes under 21%, 5% and

SUPPLEMENTARY MATERIAL. Supplementary

Supplementary Table 4 Comparison of goodness of fit criteria for Growth Mixture Models and Latent Class Growth Analysis of longitudinal BMI data fitted on the original

Forsythe NWR (HOLG), North Brigantine Natural Area (NBNA), Malibu Beach Wildlife Management Area (MWMA), Avalon-Dunes (AVDU), Stone Harbor Point (SHPT), North Wildwood (NOWI),